Global Pharmaceutical Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter pharmaceutical partnering deals.
This report provides details of the latest pharmaceutical agreements announced in the life sciences since 2018.
The report takes the reader through a comprehensive review pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.
The report presents financial deal term values for pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the pharmaceutical partnering field; both the leading deal values and most active pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 7,000 online deal records of actual pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmaceutical dealmaking since 2018, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading pharmaceutical deals since 2018. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of pharmaceutical deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of pharmaceutical partnering deals signed and announced since Jan 2018, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of pharmaceutical partnering deals signed and announced since Jan 2018. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in pharmaceutical partnering and dealmaking since 2018.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmaceutical technologies and products.
The Global Pharmaceutical Partnering Terms and Agreements 2018-2023 report provides comprehensive access to available deals and contract documents for over 7,000 pharmaceutical deals.
This report provides details of the latest pharmaceutical agreements announced in the life sciences since 2018.
The report takes the reader through a comprehensive review pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.
The report presents financial deal term values for pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the pharmaceutical partnering field; both the leading deal values and most active pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 7,000 online deal records of actual pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmaceutical dealmaking since 2018, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading pharmaceutical deals since 2018. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of pharmaceutical deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of pharmaceutical partnering deals signed and announced since Jan 2018, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of pharmaceutical partnering deals signed and announced since Jan 2018. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in pharmaceutical partnering and dealmaking since 2018.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmaceutical technologies and products.
Key benefits
Global Pharmaceutical Partnering Terms and Agreements 2018-2023 provides the reader with the following key benefits:
- In-depth understanding of pharmaceutical deal trends since 2018
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual pharmaceutical contracts entered into by leading biopharma companies
- Identify most active pharmaceutical dealmakers since 2018
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Pharmaceutical Partnering Terms and Agreements 2018-2023 is intended to provide the reader with an in-depth understanding and access to pharmaceutical trends and structure of deals entered into by leading companies worldwide.Pharmaceutical Partnering Terms and Agreements includes:
- Trends in pharmaceutical dealmaking in the biopharma industry since 2018
- Access to headline, upfront, milestone and royalty data
- Access to pharmaceutical contract documents
- Leading pharmaceutical deals by value since 2018
- Most active pharmaceutical dealmakers since 2018
In Global Pharmaceutical Partnering Terms and Agreements 2018-2023, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
The Global Pharmaceutical Partnering Terms and Agreements 2018-2023 report provides comprehensive access to available deals and contract documents for over 7,000 pharmaceutical deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in pharmaceutical dealmaking
2.1. Introduction
2.2. Pharmaceutical partnering over the years
2.3. Most active pharmaceutical dealmakers
2.4. Pharmaceutical partnering by deal type
2.5. Pharmaceutical partnering by therapy area
2.6. Pharmaceutical partnering by technology type
2.7. Deal terms for pharmaceutical partnering
2.7.1 Pharmaceutical partnering headline values
2.7.2 Pharmaceutical deal upfront payments
2.7.3 Pharmaceutical deal milestone payments
2.7.4 Pharmaceutical royalty rates
Chapter 3 - Leading pharmaceutical deals
3.1. Introduction
3.2. Top pharmaceutical deals by value
Chapter 4 - Most active pharmaceutical dealmakers
4.1. Introduction
4.2. Most active pharmaceutical dealmakers
4.3. Most active pharmaceutical partnering company profiles
Chapter 5 - Pharmaceutical contracts dealmaking directory
5.1. Introduction
5.2. Pharmaceutical contracts dealmaking directory
Chapter 6 - Pharmaceutical dealmaking by technology type
Appendices
Appendix 1 - Pharmaceutical deals by company A-Z
Appendix 2 - Pharmaceutical deals by stage of development
Appendix 3 - Pharmaceutical deals by deal type
Appendix 4 - Pharmaceutical deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further reading
Table of figures
Figure 1: Pharmaceutical partnering since 2018
Figure 2: Active pharmaceutical dealmaking activity- 2018 to 2023
Figure 3: Pharmaceutical partnering by deal type since 2018
Figure 4: Pharmaceutical partnering by disease type since 2018
Figure 5: Pharmaceutical partnering by technology type since 2018
Figure 6: Pharmaceutical deals with a headline value
Figure 7: Pharmaceutical deals with an upfront value
Figure 8: Pharmaceutical deals with a milestone value
Figure 9: Pharmaceutical deals with a royalty rate value
Figure 10: Top pharmaceutical deals by value since 2018
Figure 11: Most active pharmaceutical dealmakers 2018 to 2023
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
